Form 4: enGene Interim CMO William Grossman Receives Stock Options

Interim Chief Medical Officer William Grossman was granted 231,000 stock options by enGene Therapeutics Inc. on June 16, 2026.

Summary

• William Grossman, Interim Chief Medical Officer and Director, received two separate stock option grants totaling 231,000 shares.
• A grant of 31,000 options was issued for his service as a non-executive director.
• A grant of 200,000 options was issued in connection with his appointment as Interim Chief Medical Officer.
• Both grants have an exercise price of $1.75 per share and an expiration date of June 16, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company fundamentals.

Positives

• Alignment of interests between the Interim Chief Medical Officer and shareholders through equity-based compensation.
• Standardized compensation structure for non-executive director service.

Negatives

• Potential for future share dilution upon the exercise of the 231,000 granted options.

Risks

• Vesting of the 200,000 CMO options is contingent upon continued service, creating a retention risk if the executive departs.
• Market price volatility could impact the value of these options relative to the $1.75 exercise price.

Future Outlook

The options vest over a period of one year, incentivizing the reporting person's continued service as Interim Chief Medical Officer and Director through at least mid-2027.

Management Comments

• The 31,000 options vest fully on the earlier of the first anniversary of the vesting commencement date or the 2027 annual meeting.
• The 200,000 options vest monthly over 12 months, subject to continued service as Interim Chief Medical Officer.

Industry Context

StockSavvy.ai notes that equity grants for interim executives and board members are standard practice in the biotechnology sector to ensure leadership stability during transitional periods.

Comparison to Industry Standards

• The use of time-based vesting for executive options is consistent with standard corporate governance practices in the life sciences industry.
• The grant size is typical for mid-cap or small-cap biotech firms seeking to retain specialized medical leadership.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised.

Next Steps

• Vesting of director options by the 2027 annual meeting.
• Monthly vesting of CMO options over the next 12 months.

Key Dates

Keywords

enGene, ENGN, Form 4, Insider Trading, Stock Options, Biotech, Executive Compensation